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Characterisation of small molecule 
ligands 4CMTB and 2CTAP as 
modulators of human FFA2 
receptor signalling
Zoe V. Schofield1, Daniel Croker1,2, Avril A. B. Robertson  3, Nicholas L. Massey1, 
Chantal Donovan4, Ernest Tee1, David Edwards1, Trent M. Woodruff  2, Reena Halai1, 
Philip M. Hansbro4 & Matthew A. Cooper  1
Short chain fatty acids (SCFAs) are protective against inflammatory diseases. Free fatty acid receptor 2 
(FFA2), is a target of SCFAs however, their selectivity for FFA2 over other FFA receptors is limited. This 
study aimed to functionally characterise 2-(4-chlorophenyl)-3-methyl-N-(thiazole-2-yl)butanamide 
(4CMTB) and 4-((4-(2-chlorophenyl)thiazole-2-yl)amino)-4oxo-3-phenylbutanoic acid (2CTAP), and their 
enantiomers, in modulating FFA2 activity. The racemic mixture (R/S) and its constituents (R-) and (S-) 
4CMTB or 2CTAP were used to stimulate human (h)FFA2 in the absence or presence of acetate. Calcium 
ions (Ca2+), phosphorylated extracellular signal-regulated kinase 1 and 2 (pERK1/2) and cyclic adenosine 
monophosphate (cAMP) were measured. R/S-4CMTB is a functionally selective ago-allosteric ligand 
that enhances Ca2+ response to acetate. Both R/S-4CMTB and S-4CMTB are more potent activators 
of pERK1/2 and inhibitors of forskolin-induced cAMP than acetate. S-4CMTB increased neutrophil 
infiltration in intestinal ischemia reperfusion injury (IRI). 2CTAP inhibited constitutive Ca2+ levels, 
antagonised acetate-induced pERK1/2 and prevented damage following IRI. This study characterises 
enantiomers of functionally selective ligands for FFA2 in cells stably expressing hFFA2. It highlights the 
novel roles of selective FFA2 enantiomers 4CMTB and 2CTAP on Ca2+, pERK1/2 and cAMP and their roles 
as allosteric modulators which, may assist in efforts to design novel therapeutic agents for FFA2-driven 
inflammatory diseases.
Short chain fatty acids (SCFAs) impart protective effects in inflammatory diseases such as colitis, asthma and 
arthritis1. They act on many cell types, including neutrophils, principally by acting on free fatty acid receptors 
(FFARs). Free fatty acid receptor 2 (FFA2/FFAR2) is a classical G protein-coupled receptor (GPCR) that signals 
through Gα proteins. It is highly expressed on cells expressing intestinal peptide YY (PYY) and glucagon-like 
peptide-1 (GLP-1); viz. endocrine L-cells, basal crypts, colonocytes and enterocytes of the small and large intes-
tine2,3. Most studies have probed the role of FFA2 in metabolic disorders4,5. However, the highest expression of 
FFA2 is found in innate immune cells, especially in neutrophils, eosinophils, monocytes and B-lymphocytes2,6,7. 
This suggests that the receptor may also have a role in innate immunity and inflammation. This has led to studies 
of FFA2 in inflammatory disorders such as inflammatory bowel disease8, colon cancer9, asthma10 and arthritis11. 
The role of FFA2 as a regulator of inflammation is further supported by observations of FFA2-deficient mice 
(FFA2−/−), which exhibit exacerbated or non-resolving inflammation in colitis, arthritis and asthma models11.
Acetate, propionate and butyrate elicit FFA2-dependent chemotaxis of immune cells, most notably neutro-
phils12–14. Conversely, FFA2−/− mice are more prone to inflammation in DSS-induced colitis12. These potential dis-
crepancies are likely due to the role of neutrophils in acute versus chronic situations. FFA2 shares 43% similarity 
with FFA315 and both respond to the same SCFA ligands due to their highly conserved orthosteric sites. The order of 
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potency for FFA2 is acetate (C2) = propionate (C3) > butyrate (C4) > valerate (C5) = formate (C1), and for FFA3 is 
butyrate (C4) = propionate (C3) = valerate (C5) > acetate (C2) = formate (C1)6. FFA2 and FFA3 have different tissue 
expression profiles and physiological roles, but there remains insufficient discrimination of SCFA binding to produce 
adequate drug candidates7. Additionally, SCFAs have poor potency and high μM-mM concentrations are required to 
elicit FFA2 and FFA3 responses in vitro, which has led to the search for more potent and selective synthetic ligands.
This study fully characterises two FFA2 ligands; R-, S-, R/S- 2-(4-chlorophenyl)-3-methyl-N-(thiazole-2-yl)
butanimide (4CMTB) and 4-((4-(2-chlorophenyl)thiazole-2-yl)amino)-4oxo-3-phenylbutanoic acid (2CTAP), 
and probes their signalling profiles in CHO cells stably expressing the human FFA2 receptor (hFFA2). We demon-
strate that racemic 4CMTB is an ago-allosteric ligand, enhancing calcium ion (Ca2+) responses to acetate. R/S-
4CMTB and S-4CMTB are more potent activators of phosphorylated extracellular signal-regulated kinase 1 and 
2 (pERK1/2) and inhibitors of forskolin-induced cyclic adenosine monophosphate (cAMP), compared to ace-
tate alone. 2CTAP is an inverse agonist that inhibits constitutive Ca2+ levels and antagonises acetate-induced 
pERK1/2, but has no effect on cAMP. Conversely, at low concentrations both R- and S-4CMTB and R- and 
S-2CTAP are negative allosteric modulators of Ca2+-induced acetate responses. We report novel roles for the 
selective FFA2 enantiomers, 4CMTB and 2CTAP, on Ca2+, pERK1/2 and cAMP responses and as allosteric mod-
ulators and, highlight their activity in an in vivo intestinal ischemia reperfusion injury (IRI) model.
Results
Characterisation of R/S-4CMTB and R/S-2CTAP in CHO cells stably transfected with FFA2. 
FFA2 signals via Gαq, Gαi2,6,15 and β-arrestin16. To characterise the functional selectivity of 4CMTB and 2CTAP 
for FFA2, Ca2+, pERK and cAMP assays were carried out, with comparison to the known FFA2 agonist, acetate, 
in a CHO cell line stably transfected with hFFA2. The chemical structures of racemic 4CMTB (R/S-4CMTB) and 
2CTAP (R/S-2CTAP) and chiral separations are shown in Fig. 1. To ensure that the responses seen in these assays 
were specific for FFA2 and not activating native receptors expressed on the parental CHO-K1 cell line the FFA2 
ligands used in this study were continuously tested on the parental CHO-K1 cell line alongside CHO-FFA2 cells. 
No response was induced by acetate, 4CMTB, 2CTAP or their enantiomers in any of the assays. Responses for 
the highest concentration of the ligands seen in the parental CHO-K1 cells across Ca2+. pERK1/2 and cAMP are 
shown in Fig. 2. Acetate increased Ca2+, pERK1/2 and inhibited forskolin-induced cAMP, in a concentration-de-
pendent manner (Fig. 3, Table 1). R/S-4CMTB did not induce a Ca2+ response, however it caused a concentra-
tion-dependent increase in pERK1/2 and inhibition of forskolin-induced cAMP, with its effects more potent but 
less efficacious than acetate (Fig. 3). R/S-2CTAP caused a concentration-dependent decrease in Ca2+, however, 
had no effect on pERK1/2 or forskolin-induced cAMP (Fig. 3, Table 2).
Characterisation of enantiomers of 4CMTB and 2CTAP in CHO cells stably transfected with 
FFA2. To evaluate the functional selectivity of 4CMTB enantiomers the racemic batch was separated on a 
Phenomenex Lux Cellulose-2 chiral column. S-4CMTB elicited concentration-dependent increases in Ca2+, 
Figure 1. Chemical structures of 2-(4-chlorophenyl)-3-methyl-N-(thiazole-2-yl)butanamide (4-CMTB) and 
4-((4-(2-chlorophenyl)thiazole-2-yl)amino)-4-oxo-3-phenylbutanoic acid (2CTAP) with resolved enantiomers 
for each.
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which was more potent but less efficacious than acetate, whereas R-4CMTB had no effect on Ca2+ (Fig. 4A). 
S-4CMTB and R/S-4CMTB had similar potency and efficacy in increasing pERK1/2 (Fig. 4B) and inhibiting 
forskolin-induced cAMP (Fig. 4C). R-4CMTB was less potent than S-4CMTB and R/S-4CMTB but more potent 
than acetate. R-2CTAP and S-2CTAP both decreased Ca2+ in a similar concentration dependent manner to R/S-
2CTAP (Fig. 4A), however they had no effects on pERK1/2 or cAMP responses (Fig. 4B,C).
To study the functional selectivity of allosteric effects in a physiological setting, different concentrations of 
4CMTB were tested on an acetate dose response curve. In the Fluo-4 direct Ca2+ assay both S and R-4CMTB were 
found to be negative allosteric modulators below 1 µM. At 20 µM R-4CMTB had a mild effect on the potency of 
Figure 2. Responses for the highest concentrations of acetate, R-4CMTB, S-4CMTB and 2CTAP on parental 
CHO-K1 cells from left to right Ca2+ response, pERK1/2 response, Forskolin induced cAMP response. Ligand 
responses are plotted against positive and negative controls for each assay. Data are mean ± SEM combined 
from at least three independent experiments.
Figure 3. Biologic activity of 4CMTB and 2CTAP in Ca2+, ERK and cAMP functional assays in CHO cells 
stably expressing hFFA2. (A) Ca2+ release was detected using the Fluo-4-direct Ca2+ assay. (B) pERK1/2 
response was measured using AlphaScreen SureFire pERK1/2 (Thr202/Tyr204) assay kit. (C) Inhibition of 
forskolin-induced cAMP measured using the LANCE Ultra cAMP assay. Data were combined from at least 
three independent experiments and expressed as a percentage of the maximal response from acetate.
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acetate but did not increase the efficacy. At 20 µM S-4CMTB increased both the potency and efficacy of acetate 
(Fig. 5, Table 1).
Characterisation of the functional activity of 2CTAP. The functional nature of 2CTAP has not been 
explored beyond results from a GTPyS assay17. To confirm those findings and further investigate the functional 
nature of 2CTAP the Fluo-4 direct calcium assay, LANCE Ultra cAMP assay and a pERK1/2 assay, with a CHO 
cell line stably transfected with hFFA2 were utilised. R/S-2CTAP failed to induce intracellular Ca2+, phospho-
rylate ERK1/2 or inhibit forskolin-induced cAMP independently (Fig. 3). However, R/S-2CTAP appeared to 
inhibit constitutive Ca2+ levels. This effect was also seen with the R and S enantiomers with the S enantiomer 
having slightly higher efficacy over the R enantiomer and the recemate (Fig. 4A). Thus, indicating that 2CTAP 
could be an inverse agonist through the Gαq pathway. To fully establish the function of 2CTAP as an allosteric 
modulator we tested the effects of 2CTAP dose response curves on Ca2+ release in the presence of 2 mM acetate 
(Fig. 6). 2CTAP inhibited acetate induced Ca2+ release in a dose dependent manner and lowered the response 
below constitutive levels further supporting 2CTAP as an inverse agonist through Gαq (Fig. 6A). Acetate induced 
phosphorylation of ERK1/2 was also inhibited by 2CTAP in a dose dependent manner (Fig. 6B) suggesting that 
2CTAP is an antagonist.
The effects of functionally selective ligands in a mouse model of ischemia reperfusion injury 
(IRI). The signalling data indicates that S-4CMTB has a similar profile to acetate but is specific to FFA218 where 
as 2CTAP appears to be an antagonist and thus could offer different therapeutic advantages in disease. To fur-
ther advance the understanding of these ligands in disease we tested these ligands in the neutrophil dependent 
mouse model of superior mesenteric artery occlusion (SMOA) that represents intestinal IRI19. We confirmed an 
increase in circulating neutrophils in IRI compared to sham (Fig. 7A). Ligands dosed to sham-operated mice 
did not increase circulating neutrophils (Circulating neutrophil counts for sham-operated groups dosed with 
R-4CMTB = 0.81 × 106 ± 0.11; S-4CMTB = 0.92 × 106 ± 0.07; 2CTAP = 0.83 × 106 ± 0.09). Circulating neutro-
phil numbers in IRI groups dosed with R-4CMTB, S-4CMTB and 2CTAP were comparable to vehicle control 
IRI-groups Fig. 7A. Histological examination of haematoxylin and eosin (H&E) stained ileum sections showed 
normal mucosal villi in vehicle control and dosed sham-operated mice. In sharp contrast, mice subjected to IRI 




pEC50 Emax pEC50 Emax pEC50 Emax
Acetate 3.8 100 3.6 100 3.9 100
R/S-4CMTB — — 5.8 85 7.0 83
R-4CMTB — — 5.0 60 5.2 74
S-4CMTB 5.7 55 6.1 102 6.8 99
R/S-4CMTB + PTX — — 4.7 20
R-4CMTB + PTX — — 4.7 16
S-4CMTB + PTX — — 4.8 22
R/S-4CMTB + Acetate 3.2
R-4CMTB + Acetate 3.1
S-4CMTB + Acetate 3.6




pEC50 Emax pEC50 Emax pEC50 Emax
Agonist Acetate 3.8 100 3.6 100 3.9 100
Agonist
R/S-2CTAP — — — — — —
R-2CTAP — — — — — —
S-2CTAP — — — — — —
Antagonist
R/S-2CTAP 6.0 4.8 —
R-2CTAP 6.6 5.6 —
S-2CTAP 5.7 4.4 —
R/S-2CTAP + Acetate 6.2
R-2CTAP + Acetate 6.6
S-2CTAP + Acetate 5.8
Table 2. pEC50 and Emax values for 2CTAP through Ca2+, ERK and cAMP assays.
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by a high histopathological score. S-4CMTB did not reduce villi damage however, mucosal damage was sig-
nificantly reduced in WT IRI groups dosed with 2CTAP, and, although to a lesser degree, R-4CMTB (Fig. 7B). 
Neutrophil infiltration upon reperfusion is considered to significantly contribute to the damage caused during 
IRI20. Infiltration of neutrophils into the ileum was therefore examined by counting esterase-stained neutro-
phils and measuring myeloperoxidase (Fig. 7C and D). S-4CMTB increased neutrophil infiltration into the villi 
(Fig. 7C,D) in line with its previously shown chemotactic properties6,13. R-4CMTB and 2CTAP did not reduce 
neutrophil infiltration below the IRI group despite their protective effects, suggesting they may rather be modu-
lating neutrophil function at the site of injury. The protective effects of 2CTAP were abolished in the absence of 
FFA2 indicating that the in vivo activity observed with 2CTAP is specific to FFA2 (Fig. 7).
Discussion
Selective, allosteric, potent ligands that bind to FFA2 may have potential as therapies for inflammatory diseases. 
We characterised two reported FFA2 ligands (4CMTB and 2CTAP) and their enantiomers to assess their phar-
macological properties at hFFA2. We demonstrated that S-4CMTB is a positive allosteric modulator whereas 
R-4CMTB is a functionally selective ligand that does not activate Gαq. 2CTAP is a functionally selective inverse 
agonist that inhibits constitutive Ca2+ levels and antagonises acetate-induced ERK phosphorylation. This 
study substantially extends the previous knowledge of the activity of 4CMTB and 2CTAP by characterising the 
Figure 4. Dose response curves of 4CMTB and 2CTAP enantiomers in CHO cells stably expressing FFA2. (A) 
Ca2+ responses. (B) pERK1/2 responses. (C) Forskolin-induced cAMP. Data were combined from at least three 
independent experiments and expressed as a percentage of the maximal response from acetate.
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enantiomers of 4CMTB and 2CTAP, relative to acetate, in CHO cells stably expressing hFFA2 and in a mouse 
model of intestinal IRI.
The SCFAs acetate, propionate and butyrate activate FFA2 and FFA3 and have important roles in health and 
disease. Notably this includes their anti-inflammatory properties that are mediated through the modulation of 
chemotaxis, reactive oxygen species (ROS) and cytokine production11,14,21. Several allosteric ligands for FFA2 have 
been reported that could be developed into novel therapies17,18,22. However, these have not been characterised 
across G protein pathways and assumed function is often based on a single signalling pathway or through binding 
studies alone. FFA2 is known to signal through Gαi, Gαq and β-arrestin pathways2,15,23. Functional selectivity 
at orthosteric sites is a well characterised concept that has changed fundamental views on GPCR signalling24,25. 
Figure 5. Allosteric activity of 4CMTB enantiomers in a Ca2+ assay. Ca2+ responses were measured in the 
presence of different concentrations of acetate with varying concentrations of R-4CMTB or S-4CMTB. Data 
were combined from at least three independent experiments and expressed as a percentage of the maximal 
response from acetate.
Figure 6. Allosteric activity of 2CTAP and the enantiomers. (A) Ca2+ responses detected in a dose dependent 
manner in the presence of 2 mM acetate (dotted line) show that all enantiomers of 2CTAP reduce the signal 
below that of the basal levels. (B) ERK activation by 2 mM acetate was inhibited by all enantiomers of 2CTAP. 
(C) Forskolin-induced cAMP was not inhibited by 2CTAP nor either enantiomer. Data were combined from at 
least three independent experiments and expressed as a percentage of the maximal response from acetate.
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Although functional selectivity across allosteric sites is not as well documented, it is hypothesised that allosteric 
ligands are more likely to have biased signalling properties, which could differ again in the presence of the ortho-
steric ligand26.
This study describes the functional selectivity of two synthetic molecules for FFA2. The phenylacetamide 
compound 4CMTB from Amgen is a putative ago-allosteric agonist at FFA218, and the carboxylic acid derivatised 
variant, 2CTAP from Euroscreen, is a putative allosteric agonist at FFA2. 4CMTB has been studied across differ-
ent signalling pathways with a focus on binding assays and Gαi and Gαq pathways7,18. It has been shown to be a 
positive allosteric modulator of FFA227,28. 4CMTB is a direct FFA2 agonist in cAMP and [S35]GTPγS assays with 
100- to 1,000-fold higher affinity than acetate and propionate, but with a positive modulatory effect on acetate 
and propionate in vivo21. Other studies have reported various other effects of 4CMTB including chemotaxis of 
human6 and mouse13 neutrophils, reduced proliferation of leukaemia cells29, mediation of intracellular signalling 
in adipocytes via Gαi30 and inhibition of lipolysis in differentiated 3T3L1 cells18. The in vivo observations of 
4CMTB suggest that it is an ago-allosteric modulator, but mutational studies have failed to identify the binding 
sites of 4CMTB18,31.
2CTAP was patented as an allosteric agonist of FFA2 based on a binding assay17 with a maximal response 
at 60 nM in the GTPγS assay. It also increased glucose uptake in 3T3-L1 cells and inhibited lipolysis in isolated 
adipocytes in a concentration-dependent manner18. Acetate has been used as an endogenous ligand throughout 
these studies as it has been shown to be the most specific SCFA agonist of FFA26 with no histone deacetylase 
activity observed13.
Figure 7. The effects of R and S-4CMTB and 2CTAP in a mouse model of intestinal IRI. (A) Serum neutrophil 
numbers. (B) Quantitative histopathological scores of H&E-stained intestinal sections. (C) Neutrophil 
infiltration detected by counting esterase stained neutrophils in ileum sections. (D) Neutrophil infiltration into 
the ileum measured by myeloperoxidase. Data are mean ± SEM. ****p < 0.0001; ***p < 0.001 **p < 0.01. 
n = 7 ± 1.
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4CMTB did not induce calcium signalling in a Fluo-4 direct Ca2+ assay but did show positive cooperativ-
ity with acetate providing greater potency and increased efficacy over acetate alone. Surprisingly, 2CTAP did 
not have any agonist or ago-allosteric properties in a Ca2+ assay however it inhibited acetate-induced calcium 
responses in a dose dependent manner, suggesting that 2CTAP is an antagonist of FFA2.
The Gαq pathway and intracellular Ca2+ levels have been reported to promote neutrophil migration32 and 
the production of ROS33. Neutrophils are a common cause of damage in acute inflammatory diseases and thus 
blocking Gαq could prevent excessive neutrophil migration32 and reduce ROS production. FFA2 antagonists have 
already been reported to be able to reduce neutrophil migration17,22,34. The current study demonstrates that R-, 
S- and R/S-2CTAP can inhibit acetate-induced increases in Ca2+. In the mouse model of intestinal IRI neutrophil 
infiltration was not prevented by 2CTAP. However, mucosal damage was diminished in the IRI group dosed 
with 2CTAP and this was negated in FFA2−/− mice. The mechanism for this protection could be through 2CTAP 
blocking FFA2 induced ROS production although further investigation is required to fully elucidate the specific 
mechanisms of 2CTAP on neutrophil function.
Interestingly, the allosteric activity of R and S-4CMTB was different through the Gαq pathway. It is well estab-
lished, unfortunately due to the thalidomide tragedy, that compounds exist as a racemic mixture of (R) and (S) 
enantiomers which can have different biological activity. The subtle differences in the atomic structure mean that 
in a calcium assay S-4CMTB is an ago-allosteric ligand where R-4CMTB does not have any intrinsic ability and 
appears to be a negative allosteric modulator. This is supported by the in vivo data which showed R-4CMTB did 
not increase neutrophil infiltration and had a protective effect in IRI in contrast to S-4CMTB. Unlike R-4CMTB 
and the antagonist 2CTAP, S-4CMTB increased neutrophil infiltration corroborating the importance of the Gαq 
pathway in FFA2 induced chemotaxis.
pERK1/2 and cAMP are key downstream signalling pathways of FFA2. In neutrophils, activation of pERK1/2 
can cause the formation of neutrophil extracellular traps35, and cAMP activation leads to neutrophil chemo-
taxis36. Extracellular traps have been associated with increased damage in heart and hepatic ischemia reper-
fusion injury37,38. R, S- and R/S-4CMTB have similar potency and efficacy for pERK1/2 and partially inhibit 
forskolin-induced cAMP suggesting they are Gαi ago allosteric modulators. These responses are more potent 
than the selective FFA2 agonist acetate. 2CTAP inhibited pERK1/2 but not cAMP. Inhibition of pERK1/2 could 
contribute to the protective effects seen in vivo. Further investigation is required to fully understand the exact 
biological activity that these ligands have at each pathway and how this affects neutrophil function. However, we 
have identified 2CTAP as an antagonist that is specific at FFA2 and R and S-4CMTB which are functionally selec-
tive ligands for FFA2 and therefore present valuable tools for elucidating Ca2+, pERK1/2 and cAMP signalling 
downstream of FFA2 and the effects of FFA2 on neutrophil function.
There have been many challenges surrounding FFA2 biology, including poor potency and selectivity of lig-
ands, altered function due to the allosteric mode of action and the fact that FFA2−/− mice also have reduced 
expression of FFA3. R-, S- and R/S-4CMTB provide useful ligands to elucidate signalling bias at FFA2 at specific 
concentrations and R-, S- and R/S-2CTAP provide useful antagonists to elucidate FFA2-induced Ca2+ signalling 
in disease settings. Further studies assessing the efficacy of these compounds in rodents is warranted as some 
of the incomplete understanding of FFA2 biology is due to variability in ligand selectivity between human and 
rodent FFA221,39. However, initial studies in our mouse model of intestinal IRI support the in vitro data carried 
out on hFFA2 suggesting mouse and human homologues may have similar biological function and thus further 
investigation of these ligands in other disease models could be beneficial.
There is a need to assess enantiomeric forms of molecules, particularly targeting hFFA2 as activation of 
distinct signalling pathways may provide different biological effects. 4CMTB, reinforced the often-overlooked 
potential of enantiomers to impart different signalling properties and potential therapeutics may go unnoticed 
in a racemic mixture. S- and R/S-4CMTB are agonists at FFA2 showing similar potency and efficacy for pERK1/2 
and cAMP signalling, with S-4CMTB more potent than acetate at increasing Ca2+. 4CMTB and 2CTAP therefore 
provide useful compounds to further elucidate the translational applicability of FFA2 agonists and antagonists 
into mouse models of disease, and to clarify the discrepancies surrounding FFA2 biology. Unravelling the mech-
anisms of these pharmacologically selective ligands provides invaluable tools to further FFA2 biology and phar-
macology, particularly in neutrophil-driven disease.
Methods
CHO-K1 cells. Chinese Hamster Ovary (CHO-K1) cells were purchased from Cellank Australia as a negative 
control, as they do not endogenously express FFA2. These cells were cultured in Ham’s F12, 10% FBS and 1% pen-
icillin streptomycin. Cells were passaged when 70–80% confluent using 0.05% trypsin: EDTA in phosphate-buff-
ered saline (PBS), pH 7.4. All cells in culture, once seeded, were incubated at 37 °C with 5% CO2.
CHO-FFA2 cells. CHO-K1, stably expressing human FFA2 (CHO-FFA2) was purchased from DiscoverX 
Corporation. CHO-FFA2 cells were cultured in a buffer of Ham’s F12, 10% FBS, 1% penicillin streptomycin and 
800 μg/mL of G418 (Geneticin) (Invitrogen Life Technologies). Cells were passaged when 70–80% confluent 
using 0.05% trypsin with 1 mM EDTA in phosphate-buffered saline (PBS), pH 7.4. All cells in culture, once 
seeded, were incubated at 37 °C with 5% CO2.
FFA2 ligands. Acetate was purchased from Chem-Supply (Gillman, Australia), propionate and butyrate 
were purchased from Sigma-Aldrich (Missouri, USA). 4CMTB patented by Amgen18 and 2CTAP patented by 
Euroscreen16 were synthesized as below from purchased components.
Synthesis of 4CMTB. 4CMTB was synthesised according to the route shown in Fig. 8. where the com-
mercially available 2-aminothiazole and 2-(4-chlorophenyl)-3-methylbutanoic acid were reacted using standard 
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HBTU coupling with Hünig’s base in DMF. The desired amide 4CMTB was obtained in 70% yield after recrystal-
lization and data are consistent with literature precedent.
Synthesis of 2CTAP. 2CTAP was synthesised according to the route shown in Fig. 9. Phenylacetaldehyde (1) 
was converted to the enamine via reaction with pyrrolidine under anhydrous conditions following the procedure 
of Belanger et al.40. Subsequent reaction with t-butyl bromoacetate and sodium hydride followed by hydrolysis 
of the enamine gave the desired aldehyde (2), tert-butyl 4-oxo-3-phenylbutanoate in moderate yield over the two 
steps. Potassium permanganate was initially used as an oxidant to convert the aldehyde to the corresponding acid 
(3) however yields were exceptionally low, and reactions did not proceed cleanly. The milder Pinnick oxidation 
procedure41 gave conversion to 4-(tert-butoxy)-4-oxo-2-phenylbutanoic acid (3) in 59% yield. 4-(2-chlorophenyl)
thiazol-2-amine (5) was synthesized using standard Hantsch thiazole synthesis. Coupling of carboxylic acid (3) 
with the 2-aminothiazole (5) using standard HBTU coupling gave the protected product (4) with 93% yield after 
purification using column chromatography. Subsequent deprotection using trifluoroacetic acid gave 2CTAP in 
quantitative yield with spectra in agreement with literature. The racemic 2CTAP was separated into the two 
enantiomers using chiral column chromatography. Chiral LC-MS analyses were conducted using an Agilent 
Technologies 1200 Series Instrument with a G1316A UV-Vis detector (λ = 210 and 254 nm), 1200 Series ELSD 
and 6110 quadrupole ESI-MS, using Phenomenex Lux Cellulose-2 column (4. 6 × 250 mm, 250 Å~4.6 mm, 3 μm, 
flow rate 1 mL/min, room temperature). The eluents were 0.05% formic acid in water (A) and 0.05% formic acid 
in ACN (B). Using a 30 min isocratic method set at 60% mobile phase B. The Chiral HPLC purifications were 
achieved using a Gilson PLC 2020 Personal Purification System using a Phenomenex Lux Cellulose-2 column 
(21.2 × 150 mm, 150 Å~21.2 mm, 5 μm, flow rate 20 mL/min, room temperature). The eluents were 0.1% formic 
acid in water (A) and 0.1% formic acid in ACN (B). Using a 30 min isocratic method set at 60% mobile phase 
B. Samples were dissolved in chloroform and optical rotation was determined on an automatic polarimeter. The 
enantiomers were formulated as the sodium salt to aid their aqueous solubility in subsequent testing.
Figure 8. Synthetic route to 4CMTB.
Figure 9. Synthetic route to 2CTAP.
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Ca2+ flux assay. Fluo-4 Direct assay was preformed according to manufacturer’s instructions with additional 
wash steps and read on a Fluorescent Imaging Plate Reader (FLIPR) (Molecular Devices, California). Briefly, 
10,000 cells were seeded/well in 10 μL of media in a 384 well block with a clear bottom plate and incubated over-
night at 37 °C. An equivalent volume of 2x Flou-4 Direct calcium reagent was added to each well and incubated 
for 30 min at 37 °C and a further 30 min at room temperature. Ligand addition was carried out on the FLIPR 
instrument whilst fluorescence was measured at excitation 494 nm and emission at 516 nm for five minutes to 
enable capture of the fast calcium response.
ERK1/2 phosphorylation assay. To measure pERK1/2 we utilised the high throughput AlphaScreen 
SureFire pERK1/2 (Thr202/Tyr204) Assay Kit (PerkinElmer)42. Detection of pERK1/2 is enabled by 
immuno-sandwich capture of endogenous pERK1/2 in cell lysates. Antibody-coated AlphaScreen beads generate 
a highly amplified signal when near due to binding of pERK1/2. Cells were seeded at 50,000 cells/well in a 96 well 
tissue culture plate and incubated for 24 hours at 37 °C. Cells were then incubated in serum free media overnight. 
Test compounds were added to the cells and incubated for 10 min at room temperature before cells were lysed 
and assayed for pERK1/2 using the AlphaScreen-based detection kit according to the manufacturer’s protocol 
(PerkinElmer).
cAMP assay. The LANCE Ultra cAMP homogeneous time resolved resonance energy transfer (TR-FRET) 
immunoassay (PerkinElmer) provides a highly sensitive and robust method for the detection of cAMP. Briefly, 
cells were re-suspended in stimulation buffer (1 x HBSS, 5 mM HEPES, 0.5 mM IBMX, 0.1% BSA (pH7.4)) and 
transferred to 384-proxiplate (PerkinElmer) at a density of 2000 cells/well. Cells were stimulated with agonist and 
forskolin (5 μM), where appropriate, and incubated for 30 min. EucAMP tracer and ULight-anti-cAMP solutions 
were added to the cells and incubated for 1 hour at room temperature. Time- resolved FRET signals were meas-
ured after excitation at 320 nm on the EnVision. All data were normalized to the functional response obtained 
with 1.67 mM sodium acetate.
Conventional and FFA2 knockout mice. Specific pathogen-free (SPF) conventional C57BL/6J 
(WT) mice were obtained from the Australian Research Council (ARC) and maintained at The University of 
Queensland Biological Resources Animal Facilities under specific pathogen-free conditions.
FFA2−/− knockout mice were obtained from Monash University and bred at The University of Queensland 
Biological Resources Animal Facilities under SPF conditions. Male mice 10–12 weeks weighing 20–30 g were 
used for all experiments. All experiments were performed in accordance with the guidelines and approval of The 
University of Queensland Animal Ethics Committee.
Intestinal Ischemia Reperfusion Injury Model. Anesthetized mice underwent laparotomy followed 
by superior mesenteric artery occlusion by a loop of ligature to induce nontraumatic intestinal ischemia. After 
35 minutes the ligature was removed to allow for a reperfusion period of 150 minutes. Sham-operated mice 
underwent the same surgical procedure except for the superior mesenteric artery occlusion. Mice were orally 
gavaged with ligand 48 hours, 24 hours and 1 hour prior to surgery. Mice were euthanised and small intestinal 
tissue or whole blood [collected in 1 mg/mL EDTA and 0.1 mg/mL nafamostat mesylate (FUT-175)] was collected 
for further analysis.
Data and statistical analysis. All data is expressed as mean ± SEM from at least three independ-
ent experiments. Data analysis and curve fitting were carried out using the GraphPad Prism v6.0 soft-
ware package (GraphPad Software, California). Concentration-response data were fit to four parameter 
sigmoidal concentration-response curves. All statistical analysis of curve fit parameters was carried out by inde-
pendently fitting the data from triplicate experiments and comparing the resulting curve fit values by t-test or 
one-way-ANOVA as appropriate. Statistical differences between curves was analysed using an F-test. All statisti-
cal analysis of in vivo work was carried out using one-way anova with Tukey’s multiple comparison.
Data Availability Statement
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
References
 1. Budden, K. F. et al. Emerging pathogenic links between microbiota and the gut–lung axis. Nat. Rev. Microbiol. 15, 55–63 (2017).
 2. Brown, A. J. et al. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain 
carboxylic acids. J. Biol. Chem. 278, 11312–9 (2003).
 3. Karaki, S. et al. Expression of the short-chain fatty acid receptor, GPR43, in the human colon. J. Mol. Histol. 39, 135–142 (2008).
 4. Swaminath, G. et al. Allosteric rescuing of loss-of-function FFAR2 mutations. FEBS Lett. 584, 4208–14 (2010).
 5. Bjursell, M. et al. Improved glucose control and reduced body fat mass in free fatty acid receptor 2-deficient mice fed a high-fat diet. 
Am. J. Physiol. Endocrinol. Metab. 300, E211–20 (2011).
 6. Le Poul, E. et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell 
activation. J. Biol. Chem. 278, 25481–9 (2003).
 7. Schmidt, J. et al. Selective orthosteric free fatty acid receptor 2 (FFA2) agonists: identification of the structural and chemical 
requirements for selective activation of FFA2 versus FFA3. J. Biol. Chem. 286, 10628–40 (2011).
 8. Karaki, S. et al. Short-chain fatty acid receptor, GPR43, is expressed by enteroendocrine cells and mucosal mast cells in rat intestine. 
Cell Tissue Res. 324, 353–60 (2006).
 9. Comalada, M. et al. The effects of short-chain fatty acids on colon epithelial proliferation and survival depend on the cellular 
phenotype. J. Cancer Res. Clin. Oncol. 132, 487–497 (2006).
 10. Macia, L. et al. Microbial influences on epithelial integrity and immune function as a basis for inflammatory diseases. Immunol. Rev. 
245, 164–76 (2012).
www.nature.com/scientificreports/
1 1SCIeNTIfIC REpoRts |         (2018) 8:17819  | DOI:10.1038/s41598-018-36242-1
 11. Maslowski, K. M. et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 461, 
1282–1286 (2009).
 12. Sina, C. et al. G protein-coupled receptor 43 is essential for neutrophil recruitment during intestinal inflammation. J. Immunol. 183, 
7514–22 (2009).
 13. Vinolo, M. A. R. et al. SCFAs Induce Mouse Neutrophil Chemotaxis through the GPR43 Receptor. PLoS One 6, e21205 (2011).
 14. Vinolo, M. A. R. et al. Short-chain fatty acids stimulate the migration of neutrophils to inflammatory sites. Clin. Sci. (Lond). 117, 
331–8 (2009).
 15. Stoddart, L. A., Smith, N. J. & Milligan, G. International Union of Pharmacology. LXXI. Free fatty acid receptors FFA1, -2, and -3: 
pharmacology and pathophysiological functions. Pharmacol. Rev. 60, 405–17 (2008).
 16. Lee, S. U. et al. β-Arrestin 2 Mediates G Protein-Coupled Receptor 43 Signals to Nuclear Factor-κB. Biol. Pharm. Bull. 36, 1754–1759 
(2013).
 17. Hoveyda, H. et al. Compounds, pharmaceu- tical composition and methods for use in treating metabolic disorders. PCT Int. Appl. 
WO2010066682 (2010).
 18. Lee, T. et al. Identification and Functional Characterization of Allosteric Agonists for the G Protein-Coupled Receptor FFA2. Mol. 
Pharmacol. 74, 1599–1609 (2008).
 19. Wu, M. C. L. et al. The receptor for complement component C3a mediates protection from intestinal ischemia-reperfusion injuries 
by inhibiting neutrophil mobilization. Proc. Natl. Acad. Sci. USA 1–6, https://doi.org/10.1073/pnas.1218815110 (2013).
 20. Schofield, Z. V., Woodruff, T. M., Halai, R., Wu, M. C.-L. & Cooper, M. A. Neutrophils-a key component of ischemia-reperfusion 
injury. Shock 40, 463–70 (2013).
 21. Ulven, T. Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential therapeutic targets. Front. Endocrinol. 
(Lausanne). 3, 111 (2012).
 22. Labéguère, F., Alvey, L., Newsome, G., Laurent, S. & Fletcher, S. Novel dihydropyrimidinoisoquinolinones and pharmaceutical 
compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists) (2013).
 23. Lee, S. U. et al. β-Arrestin 2 Mediates G Protein-Coupled. Receptor 43 Signals to Nuclear. 36, 1754–1759 (2013).
 24. Kenakin, T. P. Cellular assays as portals to seven-transmembrane receptor-based drug discovery. Nat. Rev. Drug Discov. 8, 617–26 
(2009).
 25. Stallaert, W., Christopoulos, A. & Bouvier, M. Ligand functional selectivity and quantitative pharmacology at G protein-coupled 
receptors. 811–825 (2011).
 26. May, L. T., Leach, K., Sexton, P. M. & Christopoulos, A. Allosteric modulation of G protein-coupled receptors. Annu. Rev. Pharmacol. 
Toxicol. 47, 1–51 (2007).
 27. Brown, A. J. et al. Pharmacological properties of acid N-thiazolylamide FFA2 agonists. Pharmacol. Res. Perspect. 3, e00141 (2015).
 28. Hudson, B. D. et al. Defining the molecular basis for the first potent and selective orthosteric agonists of the FFA2 free fatty acid 
receptor. J. Biol. Chem. 288, 17296–17312 (2013).
 29. Bindels, L. B. et al. Gut microbiota-derived propionate reduces cancer cell proliferation in the liver. Br. J. Cancer 107, 1–8 (2012).
 30. Kimura, I. et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. 
Nat. Commun. 4, 1829 (2013).
 31. Smith, N. J. et al. Extracellular loop 2 of the free fatty acid receptor 2 mediates allosterism of a phenylacetamide ago-allosteric 
modulator. Mol. Pharmacol. 80, 163–73 (2011).
 32. Bindels, L. B., Dewulf, E. M. & Delzenne, N. M. GPR43/FFA2: physiopathological relevance and therapeutic prospects. Trends 
Pharmacol. Sci. 34, 226–232 (2013).
 33. Futosi, K., Fodor, S. & Mócsai, A. Neutrophil cell surface receptors and their intracellular signal transduction pathways. Int. 
Immunopharmacol. 17, 638–50 (2013).
 34. Pizzonero, M. et al. Discovery and optimization of an azetidine chemical series as a free fatty acid receptor 2 (FFA2) antagonist: from 
hit to clinic. J. Med. Chem. 2 (2014).
 35. Hakkim, A. et al. Activation of the Raf-MEK-ERK pathway is required for neutrophil extracellular trap formation. Nat. Chem. Biol. 
7, 75–77 (2011).
 36. Harvath, L., Robbins, J. D., Russell, A. A. & Seamon, K. B. cAMP and human neutrophil chemotaxis. Elevation of cAMP differentially 
affects chemotactic responsiveness. J. Immunol. 146, 224–32 (1991).
 37. Ge, L. et al. Neutrophil extracellular traps in ischemia-reperfusion injury-induced myocardial no-reflow: therapeutic potential of 
DNase-based reperfusion strategy. Am. J. Physiol. Circ. Physiol. 308, H500–H509 (2015).
 38. Arumugam, S., Girish Subbiah, K., Kemparaju, K. & Thirunavukkarasu, C. Neutrophil extracellular traps in acrolein promoted 
hepatic ischemia reperfusion injury: Therapeutic potential of NOX2 and p38MAPK inhibitors. J. Cell. Physiol. 233, 3244–3261 
(2018).
 39. Milligan, G., Stoddart, L. A. & Smith, N. J. Agonism and allosterism: the pharmacology of the free fatty acid receptors FFA2 and 
FFA3. Br. J. Pharmacol. 158, 146–53 (2009).
 40. Bélanger, G., Doré, M., Ménard, F. & Darsigny, V. Highly chemoselective formation of aldehyde enamines under very mild reaction 
conditions. J. Org. Chem. 71, 7481–7484 (2006).
 41. Ebbers, E. J., Ariaans, G. J. A., Bruggink, A. & Zwanenburg, B. Controlled racemization and asymmetric transformation of 
α-substituted carboxylic acids in the melt. Tetrahedron Asymmetry 10, 3701–3718 (1999).
 42. Osmond, R. I. W. et al. GPCR screening via ERK 1/2: a novel platform for screening G protein-coupled receptors. J. Biomol. Screen. 
10, 730–7 (2005).
Acknowledgements
C.D. is supported by an NHMRC Early Career Postdoctoral Fellowship. T.M.W. is supported by an NHMRC 
Career Development Fellowship. P.M.H. is supported by an NHMRC Principal Research Fellowship and a Brawn 
Fellowship, Faculty of Health & Medicine, University of Newcastle.
Author Contributions
M.C. conceived the project and directed the study program. Z.V.S. wrote the initial draft manuscript and carried 
out most of the in vitro assays and all the in vivo work. D.C. carried out some biological assays and contributed to 
manuscript writing. R.H. contributed to project planning and manuscript writing. A.R. designed the synthesis, 
wrote the synthesis sections and contributed to manuscript editing. A.R., N.M., E.T. and D.E. conducted the 
synthesis, purification and characterisation of the ligands. T.M.W. conceived and designed the in vivo experiments 
and oversaw their completion in his laboratory and contributed to project planning and manuscript editing. 
M.A.C. and C.D. co-wrote the revisions, P.M.H. contributed to planning and performing in vitro assays and 
writing and editing of the manuscript.
www.nature.com/scientificreports/
1 2SCIeNTIfIC REpoRts |         (2018) 8:17819  | DOI:10.1038/s41598-018-36242-1
Additional Information
Competing Interests: The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2018
